Ad
Search
Generic filters
Filter by content type
Taxonomy terms

TNGX – Tango Therapeutics Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.4

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 15.4

Low: 12

High: 20

Total Analysts: 5

Company Profile

Tango Therapeutics, Inc. is a precision oncology company engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). TNG908, is a synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with a methylthioadenosine phosphorylase (MTAP) deletion. MTAP-deletion occurs in all human tumors, including non-small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, cholangiocarcinoma and glioblastoma. The Company is focused on initiating a Phase I/II clinical trial. USP1 is a synthetic lethal target discovery screen for BRCA1-mutant breast cancer. The Company’s lead molecules also have activity in BRCA2-mutant patient derived xenografts, including both BRCA1 and BRCA2 mutant models that are intrinsically resistant to polymerase (PARP) inhibition.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses